Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Study to Assess the Safety and Efficacy of the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin (MK-0431-838)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Dapagliflozin;   Drug: Metformin;   Drug: Matching placebo to sitagliptin;   Drug: Matching placebo to dapagliflozin
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting - verified August 2015

Lifestyle-Related Health Outcomes in Prediabetes and Diabetes

Conditions:   Obesity;   Prediabetic State;   Type 2 Diabetes
Interventions:   Behavioral: Health Education and Coaching Strategy;   Behavioral: Dietary consult
Sponsors:   Indiana University;   Purdue University
Recruiting - verified August 2015

Adipose Tissue Imaging in Type 2 Diabetes

Condition:   Diabetes Mellitus Type 2
Interventions:   Radiation: 18F-FDG PET/CT;   Device: euglycemic clamp;   Device: hypoglycemic clamp
Sponsor:   Radboud University
Recruiting - verified August 2015

Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 Treatment

Condition:   GLP-1;Telomere-telomerase System; Par-4
Intervention:   Drug: Liraglutide
Sponsor:   Third Military Medical University
Recruiting - verified August 2015

Effects of Curcumin Supplementation on Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes

Condition:   Non Insulin Dependent Diabetes
Interventions:   Dietary Supplement: curcumin;   Dietary Supplement: Placebo
Sponsor:   National Nutrition and Food Technology Institute
Recruiting - verified July 2015

Effects of Curcumin Supplementation on Glycemic Control, Oxidative Stress, Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes

Condition:   Non Insulin Dependent Diabetes
Interventions:   Dietary Supplement: Curcumin;   Dietary Supplement: Placebo
Sponsor:   National Nutrition and Food Technology Institute
Recruiting - verified July 2015

Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Met DR;   Drug: Met IR;   Drug: Placebo
Sponsor:   Elcelyx Therapeutics, Inc.
Not yet recruiting - verified August 2015

Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

Condition:   Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
Interventions:   Drug: DPP-4 inhibiotors;   Drug: SGLT2 inhibitors;   Drug: Glimepiride
Sponsor:   Kurume University
Recruiting - verified August 2015

A 12/24-weeks Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes Mellitus
Intervention:   Biological: Bydureon
Sponsor:   AstraZeneca
Not yet recruiting - verified August 2015

Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes

Conditions:   Insulin Sensitivity;   Type 2 Diabetes
Interventions:   Drug: Rosiglitazone;   Drug: Metformin;   Drug: Placebo
Sponsors:   Turku University Hospital;   SmithKline Beecham
Completed - verified August 2015

Modulating Effects of Oil Palm Phenolics in Uncontrolled Insulin-treated Type 2 Diabetes Mellitus

Condition:   Uncontrolled Insulin-treated Type 2 Diabetes Mellitus
Intervention:   Dietary Supplement: Oil Palm Phenolics
Sponsors:   University of Science Malaysia;   Malaysia Palm Oil Board;   Clinical Research Centre, Malaysia
Not yet recruiting - verified August 2015

Improving Adherence and Commitment to Treatment in Diabetic Patients

Condition:   Type 2 Diabetes
Interventions:   Behavioral: medical team;   Behavioral: peers group;   Behavioral: SMS notification
Sponsor:   Clalit Health Services
Not yet recruiting - verified August 2015

Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin lispro;   Drug: Insulin Glargine
Sponsors:   Third Affiliated Hospital, Sun Yat-Sen University;   Guangdong Provincial Department of Science and Technology
Recruiting - verified August 2015

Short Term Dietary Serine Supplementation and Circulating Serine Levels

Condition:   Serine
Intervention:   Dietary Supplement: L-serine
Sponsor:   Massachusetts General Hospital
Not yet recruiting - verified August 2015

Human Intestinal Peptides Evaluation and Research

Conditions:   Obesity;   Diabetes Mellitus, Type 2
Intervention:   Other: blood sample analysis
Sponsor:   Turkish Metabolic Surgery Foundation
Enrolling by invitation - verified August 2015

Dietary Intervention in Type-2 Diabetes and Pre-Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Pre-diabetes;   Metabolic Syndrome
Intervention:   Other: Virta Program
Sponsor:   Virta Health
Recruiting - verified August 2015

Female Sex Hormones, Insulin Resistance and Effects of Exercise in a Human Experimental Model of Menopause

Condition:   Metabolic Syndrome
Interventions:   Behavioral: exercise;   Drug: Hormone treatment
Sponsor:   Rigshospitalet, Denmark
Not yet recruiting - verified August 2015

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified August 2015

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified August 2015

Low Calorie Diet and Diabetes

Conditions:   Diabetes Mellitus Type 2;   Dyslipidemia;   Non-alcoholic Fatty Liver Disease;   Obesity
Intervention:   Behavioral: Low calorie diet followed by life style intervention
Sponsor:   Karolinska University Hospital
Enrolling by invitation - verified August 2015

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

Conditions:   Essential Hypertension;   Type 2 Diabetes Mellitus
Intervention:   Drug: Azilsartan Medoxomil
Sponsor:   Takeda
Recruiting - verified August 2015

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Recruiting - verified August 2015

Processed Meat and Brain Regions Related to Reward and Addiction

Condition:   Type 2 Diabetes
Interventions:   Other: Processed meat hamburger;   Other: Vegan sandwich
Sponsor:   Institute for Clinical and Experimental Medicine
Not yet recruiting - verified August 2015

Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Not yet recruiting - verified August 2015

Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: 2 capsules of allopurinol 150 mg daily for 3 month;   Drug: 2 capsules of lactose daily for 3 month
Sponsor:   Hospices Civils de Lyon
Recruiting - verified August 2015

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified August 2015

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: KD026;   Drug: Placebo;   Drug: Metformin
Sponsor:   Kadmon Corporation, LLC
Recruiting - verified August 2015

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Without Control on Metformin Alone

Condition:   Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Glimepiride;   Other: Placebo
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2015

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Low Metformin;   Drug: Mid Metformin;   Drug: High Metformin;   Drug: Metformin
Sponsor:   NuSirt Biopharma
Active, not recruiting - verified August 2015

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Matching Placebo for Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified August 2015

Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria

Condition:   Diabetic Nephropathy
Interventions:   Drug: MLN1202 Placebo;   Drug: MLN1202
Sponsor:   Takeda
Not yet recruiting - verified August 2015

Multiple Ascending Dose Study in Healthy Male Subjects

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR425899;   Drug: placebo
Sponsor:   Sanofi
Recruiting - verified August 2015

Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Momordica charantia;   Drug: Placebo
Sponsor:   University of Guadalajara
Recruiting - verified August 2015

Effect of Exercise Frequency on Metabolic Control and Heart Function in Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: accumulated exercise;   Behavioral: traditional exercise
Sponsor:   Norwegian University of Science and Technology
Recruiting - verified August 2015

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GLWL-01, Part A;   Drug: Placebo, Part A;   Drug: GLWL-01, Part B;   Drug: Placebo, Part B;   Drug: GLWL-01, Part C;   Drug: Placebo, Part C
Sponsor:   GLWL Research Inc.
Recruiting - verified August 2015

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: ASP8232;   Drug: Placebo
Sponsor:   Astellas Pharma Europe B.V.
Recruiting - verified August 2015

Mechanisms of Weight Loss With SGLT2 Inhibition

Conditions:   Type 2 Diabetes;   Overweight;   Obesity
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Beth Israel Deaconess Medical Center;   Janssen Scientific Affairs, LLC
Recruiting - verified August 2015

Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Canagliflozin;   Drug: Teneligliptin;   Drug: Placebo
Sponsor:   Mitsubishi Tanabe Pharma Corporation
Recruiting - verified August 2015

Effects of Fruit Extracts on Glycaemia: The GLU-FRU Study

Condition:   Postprandial Hyperglycemia
Intervention:   Dietary Supplement: Polyphenols
Sponsor:   King's College London
Completed - verified August 2015

Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

Conditions:   Dipeptidyl-Peptidase 4 Inhibitors;   LDL Cholesterol;   Glycosylated Hemoglobin;   Diabetes Mellitus;   Coronary Disease
Interventions:   Drug: Anagliptin;   Drug: Sitagliptin
Sponsor:   Institute for Clinical Effectiveness, Japan
Recruiting - verified August 2015

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women

Condition:   Diabetes Prevention in Women After GDM Who Are at High-risk
Interventions:   Drug: DAPA/MET XR;   Drug: DAPA;   Drug: MET XR
Sponsors:   Woman's;   AstraZeneca
Recruiting - verified August 2015

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD

Conditions:   Prediabetic State;   Non-alcoholic Fatty Liver Disease;   Type 2 Diabetes Mellitus
Interventions:   Drug: Cenicriviroc 150 mg;   Drug: Matching placebo
Sponsor:   Tobira Therapeutics, Inc.
Enrolling by invitation - verified August 2015

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine U300 HOE901;   Drug: Insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified August 2015

Patient Experiences With Injection Needles

Condition:   Diabetes Mellitus, Type 2
Intervention:   Device: Subcutaneous insertions of needles
Sponsors:   University of Copenhagen;   Novo Nordisk A/S
Completed - verified August 2015

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified August 2015

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

Conditions:   Overweight;   Obesity
Interventions:   Device: Gelesis100;   Device: placebo
Sponsor:   Gelesis, Inc.
Recruiting - verified August 2015

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2963016;   Drug: LANTUS®;   Drug: Oral Antihyperglycemic Medication
Sponsors:   Eli Lilly and Company;   Boehringer Ingelheim
Recruiting - verified August 2015

An Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes

Condition:   Hypertension
Intervention:  
Sponsors:   Abbott;   Monitor Medikal Araştırma ve Danışmanlık Tic.Ltd.Şti (MonitorCRO)
Recruiting - verified August 2015

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR342434;   Drug: insulin lispro;   Drug: insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified August 2015

Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Ipragliflozin
Sponsor:   Astellas Pharma Inc
Active, not recruiting - verified August 2015

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Sitagliptin;   Drug: Placebo matching with Saxagliptin;   Drug: Placebo matching with Dapagliflozin;   Drug: Placebo matching with Sitagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified August 2015

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: LIXISENATIDE AVE0010;   Drug: metformin
Sponsor:   Sanofi
Completed - verified August 2015

Prospective Cohort Study of the Effect of Bariatric/Metabolic Surgery on Morbid Obesity Patients With Metabolic Syndrome

Conditions:   Obesity;   Metabolic Syndrome
Interventions:   Procedure: Bariatric surgery;   Other: Intensive medical therapy
Sponsor:   Hanyang University
Recruiting - verified August 2015

Sitagliptin and Glucagon Counterregulation

Condition:   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Placebo
Sponsors:   Lund University;   Merck Sharp & Dohme Corp.
Recruiting - verified October 2014

Linagliptin as Add on to Basal Insulin in the Elderly

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2015

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: Exenatide;   Drug: Exenatide matching placebo
Sponsor:   AstraZeneca
Recruiting - verified August 2015

Phase 3 28 Week Study and 24 Week Extension to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Condition:   Diabetes Mellitus
Interventions:   Drug: Exantide with Dapagliflozin;   Drug: Exentide;   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified August 2015

A Study of Once-Daily RO6811135 in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Liraglutide;   Drug: Placebo QD;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Recruiting - verified August 2015

Identify Bacteria Associated With Metabolic Diseases That Reside Both in Intestinal Crypts and in Blood

Condition:   Obesity
Interventions:   Other: obese patients;   Other: diabetic patients;   Other: patients free of obesity and diabetes;   Other: patients free type 2 diabetes
Sponsor:   University Hospital, Toulouse
Recruiting - verified August 2015

Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2015

Study of the Mechanisms of Metabolic Adaptations to Overfeeding

Conditions:   Obesity;   Diabetes
Interventions:   Other: Hypercaloric diet;   Dietary Supplement: polyphenols;   Dietary Supplement: placebo (for polyphenols)
Sponsors:   Centre Hospitalier Universitaire Vaudois;   University of Lyon
Recruiting - verified August 2015

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2015

Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Low Metformin;   Drug: Metformin;   Drug: Mid Metformin;   Drug: High Metformin
Sponsor:   NuSirt Biopharma
Active, not recruiting - verified April 2015

Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II

Condition:   Diabetes Mellitus Type II
Intervention:   Drug: e.-coli-nissle
Sponsors:   GWT-TUD GmbH;   ARDEYPHARM GmbH
Active, not recruiting - verified August 2015

Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure

Conditions:   Type 2 Diabetes Mellitus;   Hypertension
Interventions:   Drug: Placebo;   Drug: Sitagliptin;   Drug: Aprepitant;   Other: Mixed Meal Test (MMT)
Sponsor:   Vanderbilt University
Recruiting - verified August 2015

Novel Model for South Asian Treatment in Diabetes (NaMaSTe-Diabetes) Trial in Primary Care

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Culturally tailored diabetes program
Sponsors:   University of British Columbia;   Canadian Institutes of Health Research  (CIHR)
Recruiting - verified August 2015

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin medium dose;   Drug: empagliflozin high dose;   Drug: empagliflozin low dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2015

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2944876;   Drug: Exenatide extended-release;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Active, not recruiting - verified August 2015

Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management

Conditions:   Overweight;   Obese
Interventions:   Device: LLLT;   Drug: Lorcaserin
Sponsor:   Mayo Clinic
Active, not recruiting - verified August 2015

Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine

Condition:   Healthy
Interventions:   Biological: HEPLISAV;   Biological: Engerix-B
Sponsor:   Dynavax Technologies Corporation
Active, not recruiting - verified August 2015

Ertugliflozin and Sitagliptin Co-administration Factorial Study (MK-8835-005)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Matching Placebo to Ertugliflozin 5 mg;   Drug: Matching Placebo to Ertugliflozin 10 mg;   Drug: Matching Placebo to sitagliptin 100 mg;   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Sitagliptin 100 mg;   Drug: Metformin >= 1500 mg/day;   Biological: Insulin Glargine Rescue Medication;   Drug: Glimepiride Rescue Medication
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified August 2015

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2015

Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

Condition:   Diabetes Mellitus Type 2
Intervention:   Drug: Exenatide
Sponsor:   AstraZeneca
Completed - verified August 2015

DPP-4 Inhibition, Incretins and Islet Function

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Vildagliptin;   Drug: Sitagliptin
Sponsor:   Lund University
Recruiting - verified March 2015

Efficacy of a Chronic Care Model Supported by Self Monitoring of Blood Glucose With BGStar Over Usual Care in Improving Glycemic Control in Patients With Type 2 Diabetes Not Treated With Insulin

Condition:   Diabetes Mellitus
Interventions:   Device: BGStar;   Device: glucose meter
Sponsor:   Sanofi
Active, not recruiting - verified August 2015

A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

Condition:   Essential Hypertension Complicated by Type 2 Diabetes Mellitus
Interventions:   Drug: Azilsartan;   Drug: Telmisartan
Sponsor:   Takeda
Recruiting - verified August 2015

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Glimepiride;   Drug: Metformin;   Drug: Pioglitazone;   Drug: Acarbose;   Drug: Linagliptin;   Drug: Sitagliptin;   Drug: Liraglutide;   Drug: Insulin Glargine;   Drug: Exenatide once weekly (QW);   Drug: Exenatide twice daily (BID)
Sponsor:   Eli Lilly and Company
Recruiting - verified August 2015

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified August 2015

Long-term Effects of Lifestyle Intervention During Pregnancy in High Risk Women and in Their Offspring - Role of Environmental, Genetic and Epigenetic Factors

Conditions:   Type 2 Diabetes;   Obesity;   Metabolic Syndrome
Intervention:  
Sponsor:   Helsinki University
Enrolling by invitation - verified August 2015

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (15 mg);   Drug: Placebo;   Drug: Metformin;   Drug: Sitagliptin;   Drug: Glimepiride;   Biological: Insulin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified August 2015

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Active, not recruiting - verified August 2015

Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE;   Drug: Metformin;   Drug: DPP-4 inhibitor;   Drug: Sulphonylurea
Sponsor:   Sanofi
Completed - verified August 2015

A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-0893 10 mg;   Drug: MK-0893 40 mg;   Drug: MK-0893 200 mg;   Drug: MK-0893 1000 mg;   Drug: Placebo;   Biological: Sandostatine®;   Biological: Insulin;   Biological: Glucagon
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

Assessing the Effectiveness of a Weight Watchers-based Lifestyle Intervention for the Primary Prevention of Type 2 Diabetes

Conditions:   Prediabetes;   Gestational Diabetes Mellitus;   Obesity
Interventions:   Behavioral: Weight Watchers;   Behavioral: National Diabetes Education Program
Sponsors:   Indiana University;   Weight Watchers International;   Indiana Clinical and Translational Sciences Institute;   National Diabetes Education Program
Active, not recruiting - verified August 2015

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin 100 mg;   Drug: Canagliflozin 50 mg;   Drug: Canagliflozin 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified August 2015

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified August 2015

Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)

Condition:   Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Liraglutide;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

Hypoglycemia (Low Blood Sugar) and the Heart

Conditions:   Hypoglycemia;   Type 2 Diabetes
Intervention:  
Sponsor:   University of British Columbia
Recruiting - verified August 2015

Magnesium Treatment of Inflammation in Disorders of Glucose Homeostasis

Condition:   Non-Insulin Dependent Diabetes Mellitus
Intervention:   Dietary Supplement: magnesium lactate
Sponsors:   George Washington University;   The Dasman Diabetes Institute
Recruiting - verified August 2015

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (10 mg);   Drug: Placebo to Ertuglifozin;   Drug: Metformin;   Drug: Placebo to Metformin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified August 2015

Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Cardiovascular Disease
Interventions:   Drug: Sitagliptin;   Drug: Glimepiride;   Drug: Placebo;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   Merck Sharp & Dohme Corp.
Recruiting - verified August 2015

A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Withdrawn - verified August 2015

Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"

Condition:   Patients With Type 2 Diabetes Mellitus Who Have Been Examined at a Medical Institution
Intervention:   Drug: Alogliptin
Sponsor:   Takeda
Active, not recruiting - verified August 2015

Endothelial Function in Patients With Type 2 Diabetes Versus Healthy Subjects

Conditions:   Insulin Resistance;   Type 2 Diabetes
Interventions:   Other: mixed meal;   Other: Acute in vivo induced hyperinsulinemia
Sponsor:   Institute for Clinical and Experimental Medicine
Recruiting - verified August 2015

Specific Clinical Experience Investigation for Long-term Use of Bydureon

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2015

Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease

Conditions:   LVM;   Type 2 Diabetic Patients With IHD;   Endothelial Function
Interventions:   Drug: pioglitazone group;   Drug: Metformin group
Sponsor:   Xiang Guang-da
Completed - verified August 2015

Effectiveness and Cost-effectiveness of a Telemonitoring Program for Diabetic People at Home

Condition:   Type 2 Diabetes
Interventions:   Other: telemonitoring;   Other: Usual care
Sponsor:   University Hospital, Toulouse
Recruiting - verified August 2015

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2015

Insulin Therapy and Falls Due to Orthostatic Hypotension

Conditions:   Orthostatic Hypotension;   Diabetes;   Syncope
Interventions:   Other: Insulin;   Other: No Insulin
Sponsor:   University of British Columbia
Active, not recruiting - verified August 2015

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2015

Development of Novel Therapies for NIDDM

Condition:   Metabolism
Interventions:   Other: 3 Tesla;   Other: 7 Tesla
Sponsors:   Duke University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   University of Texas Southwestern Medical Center
Recruiting - verified August 2015

PMS of Trazenta on the Long-term Use as Add-on Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2015

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified August 2015

Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

Conditions:   Type 2 Diabetes Mellitus;   Hypertension;   Endothelial Dysfunction
Interventions:   Drug: Glibenclamide;   Drug: Vildagliptin
Sponsors:   Dr. José Fernando Vilela-Martin MD PhD;   Novartis
Recruiting - verified August 2015

Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease

Conditions:   Type 2 Diabetes;   Coronary Artery Disease;   Left Ventricular Mass
Intervention:   Drug: alpha-lipoic acid
Sponsor:   Wuhan General Hospital of Guangzhou Military Command
Completed - verified August 2015

A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

Metformin Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease

Condition:   Left Ventriclar Mass
Interventions:   Drug: Metformin;   Drug: placebo
Sponsor:   Wuhan General Hospital of Guangzhou Military Command
Completed - verified August 2015

Clinical Trial of Efficiency and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: Subetta;   Drug: Placebo
Sponsor:   Materia Medica Holding
Recruiting - verified August 2015

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Recruiting - verified July 2015

Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease

Conditions:   Newly Diagnosed Type 2 Diabetes;   Coronary Artery Disease
Intervention:   Drug: Sitagliptin and acarbose
Sponsor:   Wuhan General Hospital of Guangzhou Military Command
Completed - verified August 2015

Surgical Treatment in Diabetic Patients With Grade 1 Obesity

Conditions:   Obesity;   Type 2 Diabetes Mellitus
Interventions:   Procedure: Gastric bypass surgery;   Procedure: Surgical ileal transposition with sleeve;   Other: Clinical
Sponsor:   Hospital Sirio-Libanes
Completed - verified May 2013

Encourage Healthy Families

Conditions:   Gestational Diabetes Mellitus;   Pre-diabetes
Intervention:   Behavioral: Diabetes Prevention Program (DPP)
Sponsors:   Indiana University;   The JPB Foundation;   The YMCA of Greater Indianapolis;   Regenstrief Institute, Inc.;   Indiana Clinical and Translational Sciences Institute
Active, not recruiting - verified August 2015

Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2015

Study of Procoagulation Markers in Stroke Patients

Conditions:   Stroke;   Hyperglycemia;   Procoagulation Markers
Intervention:   Other: Glycemic Control
Sponsors:   Temple University;   National Institute of Neurological Disorders and Stroke (NINDS);   Neurological Emergencies Treatment Trials Network (NETT);   University of Virginia;   University of Michigan;   Medical University of South Carolina;   Georgia Regents University
Recruiting - verified August 2015

A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

Effect of Diet and Physical Activity on Incidence of Type 2 Diabetes

Conditions:   Pre-diabetes;   Obesity
Interventions:   Behavioral: High protein/ high intensity physical activity (HP-HI);   Behavioral: High protein / moderate intensity physical activity (HP-MI);   Behavioral: Moderate protein/ high intensity physical activity (MP-HI);   Behavioral: Moderate protein/ moderate intensity physical activity (MP-MI)
Sponsors:   Anne Birgitte Raben;   Helsinki University;   Maastricht University;   University of Nottingham;   University of Navarra;   Clinical Center of Endocrinology, Medical University, Sofia, Bulgaria;   University of Sydney;   University of Auckland, New Zealand;   University of Stuttgart;   Swansea University;   Cambridge Manufacturing Company Limited;   European Union
Active, not recruiting - verified August 2015

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine;   Biological: Background insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified August 2015

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Matching placebo to MK-3102;   Drug: Glimepiride;   Drug: Matching placebo to glimepiride;   Drug: Insulin glargine;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified August 2015

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: BMS-813160;   Drug: Placebo matching with BMS-813160
Sponsor:   Bristol-Myers Squibb
Completed - verified August 2015

Better Diabetes Control, Quality - Educate to Achieve Compliance

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2015

A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Omarigliptin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified August 2015

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2015

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

Condition:   Non-Alcoholic Steatohepatitis (NASH)
Interventions:   Drug: GFT505 80mg;   Drug: GFT505 120mg;   Drug: Placebo
Sponsors:   Genfit;   Naturalpha;   Premier Research Group plc
Active, not recruiting - verified August 2015

A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

PREterM FOrmula Or Donor Breast Milk for Premature Babies

Conditions:   Adiposity;   Insulin Resistance;   Metabolomic Profile;   microRNA Profile
Interventions:   Other: Unfortified Human donor Milk used to make up any shortfall in mother's own milk;   Other: Fortified Human donor Milk used to make up any shortfall in mother's own milk;   Other: Preterm Formula used when there is a shortfall in mother's own milk
Sponsor:   Imperial College London
Recruiting - verified August 2015

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: OAD;   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified August 2015

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Placebo matching with Dapagliflozin;   Drug: Saxagliptin;   Drug: Metformin immediate release (IR)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Completed - verified October 2014

Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Peer Mentoring
Sponsor:   Department of Veterans Affairs
Recruiting - verified August 2015

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: Dulaglutide;   Drug: Insulin glargine;   Drug: Insulin lispro
Sponsor:   Eli Lilly and Company
Recruiting - verified August 2015

Stress Management Among Latinos With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Behavioral: stress management
Sponsors:   Yale University;   Hartford Hospital;   University of Connecticut Health Center;   Hispanic Health Council
Completed - verified August 2015

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6807952;   Drug: RO6807952;   Drug: liraglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified August 2015

Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency

Conditions:   Type 2 Diabetes Mellitus;   Iron Deficiency
Interventions:   Drug: ferric carboxymaltose;   Drug: NaCl (0,9%)
Sponsors:   GWT-TUD GmbH;   Vifor Pharma
Recruiting - verified August 2015

Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Vildagliptin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

"Effect of High Fat and High Glycemic Diets

Condition:   Type 2 Diabetes
Interventions:   Behavioral: High Glycemic Diet;   Behavioral: Control diet
Sponsor:   Mayo Clinic
Recruiting - verified August 2015

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified August 2015

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo matching with Saxagliptin;   Drug: Metformin IR;   Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified August 2015

A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified July 2015

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: lisinopril;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6807952
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)

Condition:   Anemia
Intervention:  
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: BI1356 low dose;   Drug: BI1356 high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2015

Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin for Treatment of Type 2 DM.

Condition:   Diabetes
Interventions:   Drug: Group 1: Metformin;   Dietary Supplement: Group 2: Cinnamon Bark;   Dietary Supplement: Group 3: Cinnulin PF
Sponsor:   Mike O'Callaghan Federal Hospital
Recruiting - verified August 2015

Prevalence Study of Depression in Chinese Patients With Type 2 Diabetes (HK13)

Conditions:   Diabetes;   Depression
Interventions:   Other: Psychiatrist Interview;   Other: Depression screening - control
Sponsors:   Chinese University of Hong Kong;   Asia Diabetes Foundation
Completed - verified August 2015

JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Janumet, Lantus;   Drug: metformin, gliclazide, protaphane
Sponsor:   Chinese University of Hong Kong
Completed - verified August 2015

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: linagliptin;   Drug: glimepiride;   Drug: linagliptin placebo;   Drug: glimepride placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified August 2015

The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy

Conditions:   Nephropathy;   Cardiovascular Diseases;   Diabetes Mellitus
Interventions:   Drug: Atorvastatin;   Drug: Unikalk
Sponsor:   Erling Bjerregaard Pedersen
Completed - verified August 2015

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo (Saxagliptin);   Drug: Metformin IR;   Drug: Placebo (Metformin);   Drug: Metformin (Active Rescue)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified August 2015

Type 2 Diabetes and Obesity in Mexican Pimas: Gene-Environment Interaction

Conditions:   Type 2 Diabetes Mellitus;   Obesity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified August 2015

Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)

Condition:   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: Sitagliptin phosphate;   Drug: Comparator: Sulfonylurea;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

Outcomes of Bariatric Surgery/UMMMC Bariatric Surgery Registry

Condition:   Morbid Obesity
Intervention:   Other: Observational Study
Sponsor:   University of Massachusetts, Worcester
Completed - verified August 2015

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified August 2015

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: pioglitazone
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin (JNJ-28431754);   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Active, not recruiting - verified August 2015

Exercise in Obese Diabetic Patients With Chronic Kidney Disease

Condition:   Chronic Kidney Disease
Intervention:   Other: Structured Exercise
Sponsor:   Department of Veterans Affairs
Active, not recruiting - verified August 2015

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: RO5095932;   Drug: RO5095932
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin/Metformin FDC;   Drug: Comparator: Glimepiride;   Drug: Matching placebo to Sitagliptin/Metformin FDC;   Drug: Matching placebo to glimepiride
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)

Condition:   Type 2 Diabetes
Interventions:   Drug: sitagliptin phosphate;   Drug: Comparator: metformin;   Drug: Comparator: sitagliptin and metformin;   Drug: Comparator: placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO5095932;   Drug: RO5095932;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Condition:   Type 2 Diabetes
Interventions:   Drug: sitagliptin phosphate (+) metformin hydrochloride;   Drug: Comparator: metformin 500 mg;   Drug: Comparator: sitagliptin;   Drug: Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet;   Drug: Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet;   Drug: Comparator: metformin 1000 mg
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

PEARL Program: Empowerment Program for Patients With Type 2 Diabetes (HK4)

Condition:   Diabetes
Interventions:   Behavioral: Patient Peer Support and Empowerment;   Behavioral: Usual Care
Sponsors:   Chinese University of Hong Kong;   Asia Diabetes Foundation
Completed - verified August 2015

A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK6349;   Drug: Comparator: Placebo to MK6349
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified August 2015

Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin phosphate anhydrous formulation;   Drug: Comparator: sitagliptin phosphate monohydrate form
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: pioglitazone;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study to Examine the Pharmacokinetics, Tolerability, Safety and Efficacy of Exenatide Once Weekly Suspension

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide once weekly;   Drug: exenatide once weekly;   Other: Placebo
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified August 2015

Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)

Condition:   Diabetes Mellitus, Non-Insulin-Dependent
Interventions:   Drug: sitagliptin phosphate;   Drug: Comparator: metformin;   Drug: Comparator: metformin;   Drug: Comparator: Antidiabetic Standard of Care
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

Home-Based Walking Study in Older Adults With Type 2 Diabetes

Conditions:   Cardiovascular;   Diabetes;   Orthostatic Hypotension;   Type 2 Diabetes
Intervention:   Behavioral: Control Phase; Exercise Phase
Sponsor:   University of British Columbia
Recruiting - verified August 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO5027838;   Drug: RO5027838;   Drug: RO5093151;   Drug: RO5093151
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of Taspoglutide in Type 2 Diabetic Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: metformin;   Drug: pioglitazone;   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: exenatide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

The Joint Asia Diabetes Evaluation (JADE) Program in Hong Kong Community

Condition:   Type 2 Diabetes Mellitus
Intervention:   Other: Protocol-driven care under JADE Program
Sponsors:   Chinese University of Hong Kong;   Asia Diabetes Foundation
Completed - verified August 2015

Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial

Conditions:   Type 2 Diabetes Mellitus;   Cardiovascular Disease
Interventions:   Drug: add-on pioglitazone;   Drug: add-on sulphonylurea
Sponsors:   Italian Society of Diabetology;   Associazione Medici Diabetologi (AMD);   Associazione Nazionale Medici Cardiologi Ospedalieri
Active, not recruiting - verified August 2015

A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO4998452;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy

Conditions:   Type 2 Diabetes Mellitus;   Nephropathy
Interventions:   Drug: Valsartan;   Drug: Placebo;   Drug: Probucol
Sponsor:   Guangdong General Hospital
Recruiting - verified August 2015

Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

Condition:   Gestational Diabetes
Interventions:   Drug: Exenatide;   Genetic: Buccal/blood Sample Collection
Sponsors:   Georgetown University;   Washington Hospital Center
Withdrawn - verified August 2015

Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Comparator: Rosiglitazone;   Drug: Comparator: Placebo;   Drug: Comparator: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified August 2015

A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RG1511
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of DPP-IV (3) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4876904
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide;   Drug: sitagliptin
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified August 2015

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actos;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of Aleglitazar in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actos;   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Glyburide
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Simvastatin
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy

Conditions:   Type 2 Diabetes Mellitus;   DM Nephropathy
Intervention:   Behavioral: Multidisciplinary team care
Sponsor:   Chinese University of Hong Kong
Completed - verified August 2015

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: ethinyl estradiol and levonorgestrel; exenatide;   Drug: ethinyl estradiol and levonorgestrel; exenatide;   Drug: ethinyl estradiol and levonorgestrel; exenatide
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified August 2015

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Metformin;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

Get CardioSmart

You're Invited